Biodexa Pharmaceuticals (BDRX) Competitors $6.35 -0.26 (-3.93%) Closing price 03:59 PM EasternExtended Trading$6.08 -0.27 (-4.19%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock BDRX vs. MTEX, ATHA, BLRX, MBRX, IBIO, LPCN, IXHL, ATNF, NXTC, and BFRGShould you be buying Biodexa Pharmaceuticals stock or one of its competitors? The main competitors of Biodexa Pharmaceuticals include Mannatech (MTEX), Athira Pharma (ATHA), BioLineRx (BLRX), Moleculin Biotech (MBRX), iBio (IBIO), Lipocine (LPCN), Incannex Healthcare (IXHL), 180 Life Sciences (ATNF), NextCure (NXTC), and Bullfrog AI (BFRG). These companies are all part of the "pharmaceutical products" industry. Biodexa Pharmaceuticals vs. Its Competitors Mannatech Athira Pharma BioLineRx Moleculin Biotech iBio Lipocine Incannex Healthcare 180 Life Sciences NextCure Bullfrog AI Mannatech (NASDAQ:MTEX) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation. Which has more risk and volatility, MTEX or BDRX? Mannatech has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Is MTEX or BDRX more profitable? Biodexa Pharmaceuticals has a net margin of 0.00% compared to Mannatech's net margin of -3.46%. Biodexa Pharmaceuticals' return on equity of 0.00% beat Mannatech's return on equity.Company Net Margins Return on Equity Return on Assets Mannatech-3.46% -48.60% -10.70% Biodexa Pharmaceuticals N/A N/A N/A Does the media prefer MTEX or BDRX? In the previous week, Mannatech and Mannatech both had 1 articles in the media. Biodexa Pharmaceuticals' average media sentiment score of 1.91 beat Mannatech's score of 0.95 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Mannatech Positive Biodexa Pharmaceuticals Very Positive Which has stronger earnings & valuation, MTEX or BDRX? Mannatech has higher revenue and earnings than Biodexa Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMannatech$117.87M0.14$2.49M-$2.04-4.13Biodexa Pharmaceuticals$470K8.38-$7.32MN/AN/A Do insiders and institutionals have more ownership in MTEX or BDRX? 13.0% of Mannatech shares are held by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 41.5% of Mannatech shares are held by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryBiodexa Pharmaceuticals beats Mannatech on 7 of the 10 factors compared between the two stocks. Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDRX vs. The Competition Export to ExcelMetricBiodexa PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.09M$3.09B$5.65B$10.33BDividend YieldN/A2.44%5.79%4.65%P/E RatioN/A7.9057.5322.55Price / Sales8.38453.76561.59135.97Price / CashN/A44.6837.1160.83Price / Book2.189.7412.416.36Net Income-$7.32M-$52.93M$3.29B$270.97M7 Day Performance-3.93%3.87%1.26%0.36%1 Month Performance13.80%7.65%3.84%6.37%1 Year PerformanceN/A20.14%61.01%28.46% Biodexa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDRXBiodexa Pharmaceuticals0.6543 of 5 stars$6.35-3.9%N/AN/A$4.09M$470K0.0020Positive NewsMTEXMannatech0.9213 of 5 stars$8.55-0.1%N/A+13.0%$16.25M$117.87M-4.19250Gap UpATHAAthira Pharma1.0259 of 5 stars$4.08+5.7%$4.00-2.0%-12.8%$16.15MN/A-0.2640BLRXBioLineRx3.4198 of 5 stars$3.75-3.2%$26.00+594.3%-85.2%$15.95M$28.94M-0.4340Positive NewsGap UpMBRXMoleculin Biotech2.9942 of 5 stars$0.42+3.4%$4.00+847.9%-81.8%$15.50MN/A0.0020News CoverageIBIOiBio1.2319 of 5 stars$0.78-3.3%$5.00+537.8%-57.2%$15.41M$400K-0.45100Gap DownLPCNLipocine3.5294 of 5 stars$2.83-1.0%$9.00+218.0%-43.5%$15.29M$11.20M-3.2410News CoveragePositive NewsGap UpIXHLIncannex Healthcare0.4198 of 5 stars$0.52-2.5%N/A-70.5%$15.25M$10K-0.433Positive NewsUpcoming EarningsATNF180 Life SciencesN/A$2.40-5.1%N/A+30.5%$14.49MN/A-0.167Gap DownNXTCNextCure4.7625 of 5 stars$5.43-2.4%$25.50+370.0%-64.8%$14.49MN/A-0.2190Positive NewsBFRGBullfrog AI1.0769 of 5 stars$1.41-4.7%N/A-50.9%$14.45M$60K-1.864News CoverageGap Up Related Companies and Tools Related Companies Mannatech Competitors Athira Pharma Competitors BioLineRx Competitors Moleculin Biotech Competitors iBio Competitors Lipocine Competitors Incannex Healthcare Competitors 180 Life Sciences Competitors NextCure Competitors Bullfrog AI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BDRX) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqOn September 30, 2025, at midnight ET... a groundbreaking emergency order goes into effect, issued directly by...Altimetry | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondMost “hot AI stocks” will vanish — but Weiss Ratings’ system, ranked #1 for accuracy, just flagged 10 AI stock...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals PLC Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
